Skip to main content

Multiple Sclerosis Spasticity and cannabis in Connecticut

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
Up to 5 oz at home; phy…
POSSESSION
$100/yr
STATE FEE
3–14 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Connecticut statute and program

The Connecticut Medical Marijuana Program is the operating authority for Connecticut patient certification. The authoritative legal text is: Conn. Gen. Stat. § 21a-408 et seq.: Medical Marijuana.

What the evidence says about cannabis and Multiple Sclerosis Spasticity

The 2017 NASEM consensus report found substantial evidence that oral cannabinoids improve patient-reported spasticity symptoms in adults with MS. Clinician-rated outcomes show smaller effects than patient-reported outcomes, suggesting a meaningful subjective benefit even where objective measures change less.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Multiple Sclerosis Spasticity page.

How to qualify in Connecticut

The Connecticut Medical Marijuana Program requires the following registration steps for a Multiple Sclerosis Spasticity patient (or any qualifying diagnosis):

  1. Get certified by a Connecticut-licensed physician, APRN, PA, dentist, or podiatrist. A Connecticut-licensed practitioner registered with the Department of Consumer Protection (DCP) Medical Marijuana Program must evaluate the patient and certify the qualifying condition through the DCP physician portal. Telehealth certifications are accepted when the practitioner has a bona-fide treatment relationship with the patient.
  2. Register through the DCP patient portal. After certification, the patient completes the online registration at the DCP Medical Marijuana Program portal, uploads a Connecticut driver license or state ID, and submits a passport-style photograph. Caregivers register through the same portal and undergo a state and federal criminal background check.
  3. Pay the $100 state registration fee and receive the temporary certificate. The annual state registration fee is $100, paid by credit card or check at portal submission. A temporary certificate is issued by email within several business days and is accepted by Connecticut medical dispensaries pending arrival of the physical card. The card is renewed annually with a new physician certification and fee payment.
  4. Purchase from a Connecticut medical dispensary. With the temporary certificate or physical card, patients may purchase up to the physician-set monthly allocation (default 2.5 ounces per month) from any of Connecticut's licensed medical dispensaries. Adult-use retail also exists statewide; the medical card preserves access to medical-only products, lower taxation, and protections at workplaces and in family-law matters.
State registration fee
$100
Physician visit (typical)
$150–$300
Certification to card
3–14 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Connecticut registration steps, fees, and reciprocity rules, see the Connecticut cannabis-laws page.

ICD-10 code

A certifying physician documenting Multiple Sclerosis Spasticity for the Connecticut medical cannabis program will typically record ICD-10 G35 or SNOMED-CT 24700007 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Connecticut list Multiple Sclerosis Spasticity as a qualifying condition for medical cannabis?

Yes. Connecticut explicitly lists Multiple Sclerosis Spasticity as a qualifying condition under Connecticut Medical Marijuana Program. A patient with a documented Multiple Sclerosis Spasticity diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Connecticut rules.

How do I get a Connecticut medical marijuana card for Multiple Sclerosis Spasticity?

Step one is finding a physician licensed in Connecticut who is registered with Connecticut Medical Marijuana Program and willing to evaluate Multiple Sclerosis Spasticity cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Connecticut does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Multiple Sclerosis Spasticity?

For Multiple Sclerosis Spasticity, evidence is described as strong (e.g. multiple randomized controlled trials or systematic reviews supporting effect). The mmjnow condition page for Multiple Sclerosis Spasticity lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Multiple Sclerosis Spasticity should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Multiple Sclerosis Spasticity and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Multiple Sclerosis Spasticity; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Conn. Gen. Stat. § 21a-408 et seq.: Medical Marijuanaaccessed May 16, 2026
  2. Senate Bill 1201 (2021): Responsible and Equitable Regulation of Adult-Use Cannabis Actaccessed May 16, 2026
  3. Connecticut Department of Consumer Protection: Cannabisaccessed May 16, 2026
  4. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 14, 2026

    “Substantial evidence that oral cannabinoids are effective for improving patient-reported MS spasticity symptoms.”

  5. National MS Society: Marijuanaaccessed May 14, 2026